Uncategorized Archives - Page 33 of 142

ThursdayMay 25, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results

Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022 Achievements realized to date leave CEO Amir Reichman optimistic about the company’s growth potential and ability to deliver value to shareholders The company enjoys definitive, exclusive agreements including options for exclusive worldwide licenses with the Max Planck Society and the University Medical Center Göttingen, Germany to enable it to build a pipeline of ‘biobetter’ nanosized VHH antibodies (“NanoAbs”) Pipeline to target diseases with attractive commercial opportunities such as psoriasis, psoriatic arthritis, COVID-19, macular degeneration and asthma Biotechnology innovator BiondVax…

WednesdayMay 24, 2023 10:30 am

NextPlat Corp. (NASDAQ: NXPL) Inks Deal to Open Doors for US Business to ‘Mammoth’ Chinese Consumer Market

NextPlat, Tmall Global sign merchant sourcing agreement designed to give U.S. businesses easy access to Chinese e-commerce market. Tmall Global e-commerce platform will provide NextPlat customers a turnkey solution to sell products to the Chinese consumer market. Starting in Florida, NextPlat intends to expand E-Commerce Development Program businesses throughout the United States and all of the Americas. Turnkey international e-commerce solution simplifies the process, provides American-based companies opportunity of new business in China. In a collaboration designed to be the “first in a series of new e-commerce development programs,” global e-commerce provider NextPlat (NASDAQ: NXPL) and Alibaba Group Holding Limited…

WednesdayMay 17, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments,…

WednesdayMay 10, 2023 9:00 am

NextPlat Corp. (NASDAQ: NXPL) Is ‘One to Watch’

NextPlat is led by a highly experienced management team, board of directors and advisors with proven expertise in M&A, finance, e-commerce, media, technology and health care The company operates a state-of-the-art e-commerce platform serving customers in over 195 countries NextPlat recently announced a new e-commerce development program in collaboration with Alibaba’s Tmall Global to provide American businesses easy access to the Chinese consumer market, with plans to expand throughout the Americas Positioned as the e-commerce platform of the future, NextPlat’s system is now being upgraded with Web3 capabilities to seamlessly enable the sale of both tangible and digital assets Its…

TuesdayApr 25, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development and Manufacturing Organization Services

BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as analytical model development and analytical testing This is made possible by BiondVax’s state-of-the-art assets in Jerusalem, Israel, including GMP-ready production clean rooms, fermentors, WFI, analytic tools, media, and buffer preparations With a combined 17 years of experience in recombinant protein process development from bench to Phase 3, BiondVax’s boutique CDMO service is well positioned to meet client needs BiondVax Pharmaceuticals (NASDAQ:…

FridayApr 21, 2023 9:00 am

Progressive Care Inc. (RXMD) Technology Solutions May Spark Rapid Expansion

RMXD news indicates that a synergistic tech-healthcare collaboration with potential to ignite both growth and revenues is in the works “Restructuring whiz” takes the helm as CEO, board chair Through technology and proven processes, Progressive Care helps simplify chaos, improve care and reduce costs Recent developments bode well for the future of Progressive Care (OTCQB: RXMD). On a mission to snag ever more market share using data management and analytical tools, the well-established healthcare company might be on the cusp of breaking out of slow-growth mode and into rapid expansion. Several factors are at play that could prove meaningful for…

ThursdayApr 20, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza candidate, and built, owns, and operates its GMP biologics manufacturing facility BiondVax has an exclusive collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), to develop a pipeline of innovative nanosized antibody therapies BiondVax’s experience, assets, and pipeline represent a rare opportunity for a company of its size BiondVax Pharmaceuticals (NASDAQ: BVXV), a…

TuesdayApr 18, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars - the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of…

FridayApr 14, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans The in vivo results have shown that the company’s inhaled COVID-19 therapy, formulated using alpaca-derived nanosized antibodies (“NanoAbs”), resulted in milder and shorter illness, virtually eliminated the virus from the lungs, and prophylactically protected against illness Since he was appointed CEO in early 2021, Reichman…

ThursdayApr 13, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Glioblastoma (“GBM”), an aggressive and generally fatal brain cancer, has attracted attention as a significant unmet medical need because of its incurability, claiming the lives of more than 200,000 patients worldwide each year CNS Pharmaceuticals is in the middle of a potentially pivotal global Phase 2 clinical trial for its drug candidate, a novel anthracycline called Berubicin that is apparently unique in its ability to cross the blood-brain barrier to target central nervous system tumors CNS’s clinical trial sites have begun enrolling patients in the United States, France, Spain and Switzerland, with sites prepared to receive patients in Italy as…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results

NextPlat Corp. (NASDAQ: NXPL) Inks Deal to Open Doors for US Business to ‘Mammoth’ Chinese Consumer Market

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

NextPlat Corp. (NASDAQ: NXPL) Is ‘One to Watch’

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development and Manufacturing Organization Services

Progressive Care Inc. (RXMD) Technology Solutions May Spark Rapid Expansion

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Global Trial Targets Unmet Medical Need in Arresting GBM Brain Cancer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search